BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Biomed Research, Inc. Completes Refinement Of MedClose Device


10/19/2005 5:10:43 PM

TAMPA, Fla., April 6 /PRNewswire/ -- Biomed Research, Inc. (Biomed) reports completion of ergonomic refinements to MedClose(TM) Internal Puncture Closure Device (MedClose)(TM). The MedClose(TM) (http://www.medenclosure.com/) is a catheter-based debridement and biological glue delivery system designed to rapidly seal arterial puncture sites following angiography and angioplasty. The Company previously completed a supply agreement with Baxter Healthcare Corporation for the use of Tisseel(R) VH Fibrin Sealant with the MedClose(TM). Tisseel(R) is approved by the U.S Food and Drug Administration (FDA) as an adjunct to hemostasis in cardiopulmonary bypass and splenic injuries, as well as and adjunct in colostomy closure.

The Company has completed refinements to the MedClose(TM) that were identified during animal testing of devices produced during the primary design phase. While testing of the prior design confirmed rapid wound closure and excellent healing associated with Tisseel(R), several user interface issues indicated the need for further refinement before human studies could begin. Design enhancements include further miniaturization to permit use with a broader range of introducer sizes, ease of use ergonomics permitting true "single-user" operation, distal guidewire for centering the intraluminal balloon, and refinement of the patented debridement feature to initiate release and interaction of the patient's tissue factor with Tisseel(R) for rapid activation and sealing. Assembly processes for the refined MedClose(TM) are presently being validated, and when completed, animal testing will be repeated to verify and validate the design changes. Following completion of the pre-clinical and animal testing of the refined MedClose(TM), an application for a human study (IDE) permit will be filed with the FDA. The MedClose(TM) device is not presently available for sale.

Biomed Research, Inc. is a privately held corporation that provides product research, development, manufacturing and regulatory advisory services. MedClose(TM) is the proprietary property of Med Enclosure, LLC a subsidiary of CPC of America, Inc (BULLETIN BOARD: CPCF) of Sarasota, Florida. This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, and commercialization of new technologies.

Biomed Research, Inc.

CONTACT: Michael Dayton, Biomed Research, Inc., +1-813-949-6090



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES